Radioterapia no tratamento da doença de Castleman localizada

Miranda, Fabiana Accioli; Faria, Victor Hugo Chiquetto; Arruda, Gustavo Viani; Silva, Lucas Godoi Bernardes da

doi:10.1590/s1806-37132013000100019

Cited by 9 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the available literature is confined to a small number of cases, 47 – 58 as summarized in Table 2 , radiotherapy appears to be a reasonable alternative treatment option in unresectable cases of UCD. Of the 17 identified patients that were treated with radiotherapy alone, the majority received 40–45 Gy (range 27–60), with six patients achieving complete response (CR, 35%) and seven achieving partial response (PR, 41%).…”

Section: Overview Of Current Therapeutic Strategies and Outcomes Unicmentioning

confidence: 99%

Update and new approaches in the treatment of Castleman disease

Chan¹,

Lade²,

Prince³

et al. 2016

JBM

View full text Add to dashboard Cite

First described 60 years ago, Castleman disease comprises a rare and heterogeneous cluster of disorders, characterized by lymphadenopathy with unique histological features and associated with cytokine-driven constitutional symptoms and biochemical disturbances. Although unicentric Castleman disease is curable with complete surgical excision, its multicentric counterpart is a considerable therapeutic challenge. The recent development of biological agents, particularly monoclonal antibodies to interleukin-6 and its receptor, allow for more targeted disease-specific intervention that promises improved response rates and more durable disease control; however, further work is required to fill knowledge gaps in terms of underlying pathophysiology and to facilitate alternative treatment options for refractory cases.

show abstract

Section: Overview Of Current Therapeutic Strategies and Outcomes Unicmentioning

confidence: 99%